Ranchi News Desk

Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Takeda, Ovid Therapeutics Inc., Eisai, Stoke Therapeurtic

 Breaking News
  • No posts were found

Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Takeda, Ovid Therapeutics Inc., Eisai, Stoke Therapeurtic

May 10
20:12 2023
Dravet Syndrome Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight |  Key Companies - Takeda, Ovid Therapeutics Inc., Eisai, Stoke Therapeurtic
DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dravet Syndrome.

DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast

 

Some of the key facts of the Dravet Syndrome Market Report: 

  • The Dravet Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the Dravet Syndrome Foundation (2022), a new US epidemiology study found that Dravet Syndrome affects 1:15,700 infants, 80% of whom have a SCN1A mutation, making it twice as frequent as previously thought
  • The total incident cases of Dravet Syndrome were 2,800 in Japan in 2022, and this number is expected to rise by 2032
  • The total incident cases of Dravet Syndrome were 21,760 in the US in 2022, and by 2032, they are expected to rise during the forecast period 2022-32
  • Key Dravet Syndrome Companies: Takeda, Ovid Therapeutics Inc., Eisai, Stoke Therapeurtics, Zogenix, Inc., Epygenix, Jazz Pharmaceuticals, Biocodex, Longboard Pharmaceuticals, and others
  • Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ZX008 (Fenfluramine Hydrochloride), EPX-100, Soticlestat, GWP42003-P, Retrospective, LP352, and others
  • The Dravet Syndrome epidemiology based on gender analyzed that more men than women have Dravet Syndrome
  • The Dravet Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dravet Syndrome pipeline products will significantly revolutionize the Dravet Syndrome market dynamics.

 

Dravet Syndrome Overview

Dravet Syndrome (DS), according to the National Organisation for Rare Disorders (NORD), is a severe form of epilepsy marked by frequent, protracted seizures that are frequently brought on by elevated body temperatures (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other medical issues.

 

Get a Free sample for the Dravet Syndrome Market Report –

https://www.delveinsight.com/sample-request/dravet-syndrome-market

 

Dravet Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dravet Syndrome Epidemiology Segmentation:

The Dravet Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Dravet Syndrome
  • Prevalent Cases of Dravet Syndrome by severity
  • Gender-specific Prevalence of Dravet Syndrome
  • Diagnosed Cases of Episodic and Chronic Dravet Syndrome

 

Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Epidemiology Forecast

 

Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched during the study period. The analysis covers Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dravet Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Dravet Syndrome Therapies and Key Companies

  • TAK-935 (soticlestat): Takeda
  • BELVIQ (lorcaserin): Eisai
  • STK-001: Stoke Therapeurtics

 

Discover more about therapies set to grab major Dravet Syndrome market share @ Dravet Syndrome Treatment Market

 

Dravet Syndrome Market Strengths

  • The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug
  • A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes
  • Development of long-acting injectable Antipsychotics

 

Dravet Syndrome Market Opportunities

  • Demands of advanced therapeutics and presence of significant number of pipeline drugs
  • There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective
  • Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases

 

Scope of the Dravet Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Dravet Syndrome Companies: Takeda, Ovid Therapeutics Inc., Eisai, Stoke Therapeurtics, Zogenix, Inc., Epygenix, Jazz Pharmaceuticals, Biocodex, Longboard Pharmaceuticals, and others
  • Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ZX008 (Fenfluramine Hydrochloride), EPX-100, Soticlestat, GWP42003-P, Retrospective, LP352, and others
  • Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies
  • Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Dravet Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dravet Syndrome Market Access and Reimbursement 

 

To know more about Dravet Syndrome companies working in the treatment market, visit @ Dravet Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Dravet Syndrome Market Report Introduction

2. Executive Summary for Dravet Syndrome

3. SWOT analysis of Dravet Syndrome

4. Dravet Syndrome Patient Share (%) Overview at a Glance

5. Dravet Syndrome Market Overview at a Glance

6. Dravet Syndrome Disease Background and Overview

7. Dravet Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dravet Syndrome 

9. Dravet Syndrome Current Treatment and Medical Practices

10. Dravet Syndrome Unmet Needs

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Market Outlook

13. Country-Wise Dravet Syndrome Market Analysis (2019–2032)

14. Dravet Syndrome Market Access and Reimbursement of Therapies

15. Dravet Syndrome Market Drivers

16. Dravet Syndrome Market Barriers

17.  Dravet Syndrome Appendix

18. Dravet Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services